Background: Apolipoprotein E (APOE) 4 allele carriers have an increased risk of late-onset Alzheimer’s disease (AD).However, in the “Choosing Wisely” campaign for avoiding unnecessary medical tests, treatments, and procedures, APOEgenetic testing is not recommended as a predictive test for AD.Objective: The aim of this study was to investigate the potential value of APOE genetic testing in a specific clinical context.

Methods: Subjects with poor performance in the Korean version of the Mini-Mental Status Examination for dementiascreening (MMSE-DS) with a Z-score of less than –1.5 were recruited from the public health centers. All participantsunderwent APOE genetic testing. Family history of dementia (FHx) was confirmed if one or more first-degree relatives haddementia.

Results: Among 349 subjects, 162 (46.4%) were diagnosed with AD. APOE 4 allele carriers had a much higher risk of AD inthe group with FHx than in the group without FHx (OR = 15.81, 95% CI = 2.74–91.21 versus OR = 1.82, 95% CI = 1.00–3.27,z = 2.293, p = 0.011). The sensitivity, specificity, positive predictive value, and negative predictive value for the APOE 4allele were 47.7%, 90.9%, 91.3%, and 46.5% in the group with FHx.

Conclusion: It would be a wise choice to perform the APOE genetic testing for the diagnosis of AD in subjects with poorperformance in a screening test and a family history of dementia.